A new era for radiolabeled antibodies in cancer?

Sally J. Denardo, Linda A. Kroger, Gerald L Denardo

Research output: Contribution to journalReview article

66 Citations (Scopus)

Abstract

Radioimmunotherapy (RIT), a therapy targeted to tumor cells, is a modality that can currently deliver radiation to tumor cells at levels 3-50-times higher than to the normal tissue with the next highest dose. RIT appears promising for future cancer therapy. Clinical responses in patients with advanced cancer have frequently been achieved with RIT as a single agent. Extended complete remissions and even increased survival have been achieved in lymphoma. Similar results in other cancers seem likely with RIT in combination therapy.

Original languageEnglish (US)
Pages (from-to)563-569
Number of pages7
JournalCurrent Opinion in Immunology
Volume11
Issue number5
DOIs
StatePublished - Oct 1 1999

Fingerprint

Radioimmunotherapy
Antibodies
Neoplasms
Lymphoma
Therapeutics
Radiation
Survival

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

A new era for radiolabeled antibodies in cancer? / Denardo, Sally J.; Kroger, Linda A.; Denardo, Gerald L.

In: Current Opinion in Immunology, Vol. 11, No. 5, 01.10.1999, p. 563-569.

Research output: Contribution to journalReview article

Denardo, Sally J. ; Kroger, Linda A. ; Denardo, Gerald L. / A new era for radiolabeled antibodies in cancer?. In: Current Opinion in Immunology. 1999 ; Vol. 11, No. 5. pp. 563-569.
@article{ba107c6dd0a947b8abc464d1f3aa2a75,
title = "A new era for radiolabeled antibodies in cancer?",
abstract = "Radioimmunotherapy (RIT), a therapy targeted to tumor cells, is a modality that can currently deliver radiation to tumor cells at levels 3-50-times higher than to the normal tissue with the next highest dose. RIT appears promising for future cancer therapy. Clinical responses in patients with advanced cancer have frequently been achieved with RIT as a single agent. Extended complete remissions and even increased survival have been achieved in lymphoma. Similar results in other cancers seem likely with RIT in combination therapy.",
author = "Denardo, {Sally J.} and Kroger, {Linda A.} and Denardo, {Gerald L}",
year = "1999",
month = "10",
day = "1",
doi = "10.1016/S0952-7915(99)00017-5",
language = "English (US)",
volume = "11",
pages = "563--569",
journal = "Current Opinion in Immunology",
issn = "0952-7915",
publisher = "Elsevier Limited",
number = "5",

}

TY - JOUR

T1 - A new era for radiolabeled antibodies in cancer?

AU - Denardo, Sally J.

AU - Kroger, Linda A.

AU - Denardo, Gerald L

PY - 1999/10/1

Y1 - 1999/10/1

N2 - Radioimmunotherapy (RIT), a therapy targeted to tumor cells, is a modality that can currently deliver radiation to tumor cells at levels 3-50-times higher than to the normal tissue with the next highest dose. RIT appears promising for future cancer therapy. Clinical responses in patients with advanced cancer have frequently been achieved with RIT as a single agent. Extended complete remissions and even increased survival have been achieved in lymphoma. Similar results in other cancers seem likely with RIT in combination therapy.

AB - Radioimmunotherapy (RIT), a therapy targeted to tumor cells, is a modality that can currently deliver radiation to tumor cells at levels 3-50-times higher than to the normal tissue with the next highest dose. RIT appears promising for future cancer therapy. Clinical responses in patients with advanced cancer have frequently been achieved with RIT as a single agent. Extended complete remissions and even increased survival have been achieved in lymphoma. Similar results in other cancers seem likely with RIT in combination therapy.

UR - http://www.scopus.com/inward/record.url?scp=0032844393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032844393&partnerID=8YFLogxK

U2 - 10.1016/S0952-7915(99)00017-5

DO - 10.1016/S0952-7915(99)00017-5

M3 - Review article

C2 - 10508716

AN - SCOPUS:0032844393

VL - 11

SP - 563

EP - 569

JO - Current Opinion in Immunology

JF - Current Opinion in Immunology

SN - 0952-7915

IS - 5

ER -